Tianjin Lisheng PharmaceuticalLtd Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Fujun Wang

Amministratore delegato

CN¥1.0m

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	7.3yrs
Proprietà del CEO	0.02%
Durata media del management	4yrs
Durata media del Consiglio di amministrazione	2.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

These 4 Measures Indicate That Tianjin Lisheng PharmaceuticalLtd (SZSE:002393) Is Using Debt Safely

Sep 28

Tianjin Lisheng PharmaceuticalLtd (SZSE:002393) Strong Profits May Be Masking Some Underlying Issues

Mar 28

AMMINISTRATORE DELEGATO

Fujun Wang (56 yo)

7.3yrs

Mandato

CN¥1,026,000

Compensazione

Mr. Fujun Wang has been a Non-Independent Director of Tianjin Lisheng Pharmaceutical Co.,Ltd. since August 17, 2017 and serves as its General Manager.

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Fujun Wang	GM & Non-Independent Director	no data	CN¥1.03m	0.022% CN¥ 997.2k
Jiaying Wang	Financial Director & Accounting Supervisor	3.1yrs	CN¥602.30k	0.018% CN¥ 797.7k
Feifei Ma	Secretary of the Board	10.9yrs	CN¥718.50k	0.018% CN¥ 797.7k
Changfeng Long	Chief Engineer & Deputy GM	4.8yrs	CN¥802.20k	0.018% CN¥ 797.7k
Xiaoyan Guo	Deputy General Manager	no data	CN¥729.20k	0.018% CN¥ 797.7k
Jiankang Liang	Deputy General Manager	2.2yrs	CN¥528.50k	0.018% CN¥ 797.7k

4.0yrs

Durata media

49.5yo

Età media

Gestione esperta: Il team dirigenziale di 002393 è considerato esperto (durata media dell'incarico 4 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Fujun Wang	GM & Non-Independent Director	7.3yrs	CN¥1.03m	0.022% CN¥ 997.2k
Qian Wang	Director	1.5yrs	CN¥781.70k	0.018% CN¥ 797.7k
Kexiang Yu	Non-Independent Director	2.8yrs	Nessun dato	Nessun dato
Ying Lei	Independent Director	2.9yrs	CN¥60.00k	Nessun dato
Jianxin Fang	Independent Director	3.9yrs	CN¥60.00k	Nessun dato
Mei Zhang	Independent Director	3.9yrs	CN¥60.00k	Nessun dato
Liyan Zhu	Supervisor	2.3yrs	Nessun dato	Nessun dato
Ping Zhang	Chairman of the Board	2yrs	CN¥833.00k	0.022% CN¥ 997.2k
Fei Teng	Director	1.5yrs	Nessun dato	Nessun dato
Lijun Sun	Chairman of the Board of Supervisors	1.5yrs	Nessun dato	Nessun dato
Hao Liu	Director	2.3yrs	Nessun dato	Nessun dato
Qiong Wang	Supervisor	1.6yrs	Nessun dato	Nessun dato

2.3yrs

Durata media

52yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 002393 non è considerato esperto (durata media del mandato 2.3 anni), il che suggerisce un nuovo consiglio.

Tianjin Lisheng PharmaceuticalLtd Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Tianjin Lisheng Pharmaceutical Co.,Ltd., Annual General Meeting, May 16, 2024

High number of new directors

High number of new and inexperienced directors

Tianjin Lisheng Pharmaceutical Co.,Ltd. Approves Executive Changes

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.26 (vs CN¥0.98 in 3Q 2023)

Tianjin Lisheng Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 23%

These 4 Measures Indicate That Tianjin Lisheng PharmaceuticalLtd (SZSE:002393) Is Using Debt Safely

Second quarter 2024 earnings released: EPS: CN¥0.17 (vs CN¥0.17 in 2Q 2023)

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14) completed the acquisition of additional 15% stake in Tianjin Pharmaceutical Group Finance Co., Ltd from Tianjin Lisheng Pharmaceutical Co.,Ltd. (SZSE:002393).

Grand Pharmaceutical (China) Co., Ltd. completed the acquisition of 24.65% stake in Tianjin Tanabe Seiyaku Co, Ltd. from Tianjin Lisheng Pharmaceutical Co.,Ltd.

Grand Pharmaceutical (China) Co., Ltd. completed the acquisition of 24.65% stake in Tianjin Tanabe Seiyaku Co, Ltd. from Tianjin Lisheng Pharmaceutical Co.,Ltd.

Tianjin Lisheng Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Aug 23, 2024

Lishen Releases 5MWh AC and DC Integrated Energy Storage System and New Generation of Wall-Mounted Residential Energy Storage Product

Tianjin Lisheng Pharmaceutical Co.,Ltd., Annual General Meeting, May 16, 2024

First quarter 2024 earnings released: EPS: CN¥0.32 (vs CN¥0.25 in 1Q 2023)

Tianjin Lisheng Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Tianjin Lisheng PharmaceuticalLtd (SZSE:002393) Strong Profits May Be Masking Some Underlying Issues

Full year 2023 earnings released: EPS: CN¥1.96 (vs CN¥0.51 in FY 2022)

Investor sentiment deteriorates as stock falls 20%

Tianjin Lisheng Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024

New minor risk - Earnings quality

Third quarter 2023 earnings released: EPS: CN¥1.37 (vs CN¥0.23 in 3Q 2022)

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14) agreed to acquire additional 15% stake in Tianjin Pharmaceutical Group Finance Co., Ltd from Tianjin Lisheng Pharmaceutical Co.,Ltd. (SZSE:002393) for CNY 87.8 million.

Tianjin Lisheng Pharmaceutical Co.,Ltd. to Report First Half, 2023 Results on Aug 25, 2023

Tianjin Lisheng Pharmaceutical Co.,Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date Is 30 June 2023

First quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.20 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.67 in FY 2021)

Investor sentiment deteriorated over the past week

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.20 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.16 (vs CN¥0.14 in 2Q 2021)

Tianjin Lisheng Pharmaceutical Co.,Ltd. Announces Final Dividend on Share A for 2021, Payable on June 20, 2022

First quarter 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.20 in 1Q 2021)

High number of new and inexperienced directors

Tianjin Lisheng Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021

Investor sentiment improved over the past week

Tianjin Lisheng Pharmaceutical Co.,Ltd. Approves Executive Changes

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.12 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.12 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.19 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.05 (vs CN¥1.03 in FY 2019)

Tianjin Lisheng Pharmaceutical Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 24, 2021

New 90-day low: CN¥17.18

New 90-day low: CN¥18.39

New 90-day low: CN¥22.63

New 90-day low: CN¥24.15

New 90-day low: CN¥24.28

Third quarter earnings released

Tianjin Lisheng Pharmaceutical Co.,Ltd. to Report Q3, 2020 Results on Oct 27, 2020

New 90-day low: CN¥25.02

First half earnings released

New 90-day high - CN¥29.81

Tianjin Lisheng Pharmaceutical Co.,Ltd. to Report First Half, 2020 Results on Aug 24, 2020

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media